key: cord-0686661-7hmlzkav
authors: O’Morain, Neil; Coe, Carolann; Mallon, Patrick; Twomey, Patrick; De Gascun, Cillian F.; Doherty, Glen A.
title: Letter: how frequently does COVID‐19 mimic an IBD flare when community transmission of SARS‐CoV‐2 is active?
date: 2021-02-10
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.16240
sha: 5dcdd4035d8fb6e2984d97afefb7a6dde9e79cbd
doc_id: 686661
cord_uid: 7hmlzkav

LINKED CONTENT This article is linked to Taxonera et al paper. To view this article, visit https://doi.org/10.1111/apt.15804

Patients with IBD continue to present with disease flares during the COVID-19 pandemic. Our index of suspicion for considering COVID-19 as a possible cause of diarrhoea when SARS-CoV-2 community transmission should remain high. However, and reassuringly, we did not detect SARS-CoV-2 RNA in any stool samples, whether FC levels were elevated or not. These limited data suggest that

2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases

Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission

A new coronavirus associated with human respiratory disease in China

Covid-19 and the digestive system

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process

Faecal calprotectin indicates intestinal inflammation in COVID-19

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease

Letter: SARS-CoV-2-induced gastrointestinal inflammation